PTEN and prostate carcinoma: For example, in prostate cancer with PTEN deletion, Qi et al. found that intermittent administration of PI3K inhibitors, compared to daily dosing, more effectively activates CD8 + T cell-dependent antitumor immune responses, promoting sustained responses to anti-PD-1 therapy [273].